Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation

Journal of Heart and Lung Transplantation

Volumn 29, Issue 5, 2010, Pages 523-530

  Monforte, Víctor ^a,c   Ussetti, Piedad ^b   Gavaldà, Joan ^a   Bravo, Carles ^a,c   Laporta, Rosalia ^b   Len, Oscar ^a   García Gallo, Cristina López ^b   Tenorio, Lluís ^a   Solé, Joan ^a   Román, Antonio ^a,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

amphotericin B; aspergillus infection; aspergillus supp; fungal prophylaxis; lung transplantation; nebulized prophylaxis; transplantation infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; AZTREONAM; CASPOFUNGIN; CYCLOSPORIN; EVEROLIMUS; GANCICLOVIR; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FUNGAL COLONIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE LUNG ASPERGILLOSIS; LUNG ASPERGILLOSIS; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEBULIZATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; TRACHEOBRONCHITIS; TREATMENT OUTCOME; ULCER; ULCERATIVE TRACHEOBRONCHITIS;

ADMINISTRATION, INHALATION; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; COHORT STUDIES; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PULMONARY ASPERGILLOSIS;

EID: 77950518252     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.11.603     Document Type: Article

References (44)

1. Yeldandi V., Laghi F., McCabe M.A., et al. Aspergillus and lung transplantation. J Heart Lung Transplant 14 (1995) 883-890
2. Westney G.E., Kesten S., de Hoyos A., et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 61 (1996) 915-919
3. Cahill B.C., Hibbs J.R., Savik K., et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 112 (1997) 1160-1164
4. Husni R.N., Gordon S.M., Longworth D.L., et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 26 (1998) 753-755
5. Mehrad B., Paciocco G., Martinez F.J., et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 119 (2001) 169-175
6. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22 (2003) 258-266
7. Sole A., Morant P., Salavert M., et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359-365
8. Reichenspurner H., Gamberg P., Nitschke M., et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 26 (1997) 627-628
9. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 20 (2001) 1274-1281
10. Drew R.H., Dodds A.E., Benjamin Jr. D.K., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237
11. Mohammad R.A., and Klein K.C. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother 40 (2006) 2148-2154
12. Lowry C.M., Marty F.M., Vargas S.O., et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 9 (2007) 121-125
13. Dummer J.S., Lazariashvilli N., Barnes J., et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 23 (2004) 1376-1381
14. Husain S., Zaldonis D., Kusne S., et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 8 (2006) 213-218
15. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 75 (2003) 1571-1574
16. Monforte V., Ussetti P., Lopez R., et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 28 (2009) 170-175
17. Juarez J.C., Lopez R.M., Hueto M., et al. Stability of amphotericin B in water solution for inhalation. Eur Hosp Pharm 3 (1997) 59-60
18. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
19. Trulock E.P. Lung transplantation. Am J Respir Crit Care Med 155 (1997) 789-818
20. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002) 297-310
21. Calvo V., Borro J.M., Morales P., et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 115 (1999) 1301-1304
22. Guillemain R., Lavarde V., Amrein C., et al. Invasive aspergillosis after transplantation. Transplant Proc 27 (1995) 1307-1309
23. Minari A., Husni R., Avery R.K., et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 4 (2002) 195-200
24. Borro J.M., Sole A., de la T.M., et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 40 (2008) 3090-3093
25. Gavalda J., Len O., Juan R.S., et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 41 (2005) 52-59
26. Hamacher J., Spiliopoulos A., Kurt A.M., et al. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 13 (1999) 180-186
27. Mattner F., Chaberny I.F., Weissbrodt H., et al. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole]. Mycoses 48 Suppl 1 (2005) 51-55
28. Shitrit D., Ollech J.E., Ollech A., et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 24 (2005) 2148-2152
29. Husain S., Paterson D.L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 6 (2006) 3008-3016
30. Husain S., Munoz P., Forrest G., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40 (2005) 89-99
31. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16 (2003) 607-612
32. Aguilar-Guisado M., Givalda J., Ussetti P., et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 7 (2007) 1989-1996
33. Palmer S.M., Drew R.H., Whitehouse J.D., et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 72 (2001) 545-548
34. Bates D.W., and Yu D.T. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc) 39 (2003) 801-813
35. Monforte V., Román A., Gavaldà J., et al. Contamination of the nebulization systems used in the prophylaxis with amphotericin B nebulized in lung transplantation. Transplant Proc 37 (2005) 4056-4058
36. Kramer M.R., Denning D.W., Marshall S.E., et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 144 (1991) 552-556
37. Nathan S.D., Shorr A.F., Schmidt M.E., et al. Aspergillus and endobronchial abnormalities in lung transplant recipients. Chest 118 (2000) 403-407
38. Ruiz I., Gavalda J., Monforte V., et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 6 (2006) 178-182
39. Helmi M., Love R.B., Welter D., et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 123 (2003) 800-808
40. Danziger-Isakov L.A., Worley S., Arrigain S., et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant 27 (2008) 655-661
41. Ruffini E., Baldi S., Rapellino M., et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 181-190
42. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 (1998) 781-803
43. Iversen M., Burton C.M., Vand S., et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 26 (2007) 879-886
44. Agencia Española del Medicamento y Productos Sanitarios. GPT 1 Guía de Prescripción Terapéutica. Adaptación española del British National Formulary. Primera ed. Barcelona (2006) 321-326